23andMe, named after the number of chromosome pairs in humans, is a consumer genetics and research company. Co-founded by Linda Avey and Anne Wojcicki, 23andMe has plans to make the human genome searchable. The company aims to help people understand what their genes mean by indexing the genes and highlighting significant findings. Brin, along with Google, invested $3.9M into the company as part of a Series A in May of 2007. 23andMe allows its customers to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide categorized and searchable data.
How It Works
*Based on Preferred Stock Price, 23andMe does not have a stock symbol since it is currently private and is yet to have an IPO.
Human Longevity, Kallyope
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from 23andMe or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.